Mukka Proteins Subscription Status: Mukka Proteins, a fisheries company, has received an overwhelming response from investors during its initial public offering (IPO).
According to Bombay Stock Exchange (BSE) data, Mukka Proteins IPO was oversubscribed 136.99 times on the last day of IPO buying on Monday.
Mukka Proteins Subscription Status
As of the third and final day of the IPO, retail investors have subscribed 58.52 times, the non-institutional investors (NII) portion has been oversubscribed 250.38 times and the qualified institutional buyers (QIB) portion has been booked 189.28 times.
Mukka Proteins Subscription Status: On the very first day of opening of subscription, the retail investors’ portion was fully subscribed in the first two hours itself.
The total subscription rate on the first day was 2.47 times.
The retail portion was oversubscribed 3.70 times, the NII portion was oversubscribed 1.55 times and the QIB portion was oversubscribed 1.01 times.
This momentum continued on the second day and the subscription rate reached 6.97 times.
Retail investors’ portion was subscribed 10.21 times, NII portion 6.22 times and QIB portion 1.86 times.
Mukka Proteins Subscription Status: Till the close of subscription on Monday, Mukka Proteins IPO has received bids for 7,67,16,38,920 shares against the total offer of 5,60,00,435 shares.
The value of the IPO is ₹224 crore. It consists of 8,00,00,000 equity shares face value with face value of Re 1 each.
Mukka Proteins plans to invest the proceeds from the IPO for general corporate purposes, its affiliates and Ento Proteins. Besides, other needs of the company will also be fulfilled.
Mukka Proteins Subscription Status: This issue opened on 29 February and closed on 4 March.
Mukka Proteins has reserved 50% shares for qualified institutional buyers, 15% for non-institutional investors and 35% for retail investors.
The Gray Market Premium (GMP) for Mukka Proteins IPO is currently +35, indicating a premium of ₹35 in the gray market.
This suggests that Mukka Proteins shares are trading at a premium and the estimated listing price is ₹63 per share, which is 125% higher than the IPO price of ₹28.
